Summary & Overview
HCPCS J2469: Palonosetron HCl Injection, 25 mcg
HCPCS Level II code J2469 designates the injectable formulation of palonosetron hydrochloride, 25 mcg, an antiemetic used primarily to prevent chemotherapy-induced nausea and vomiting. Nationally, this code matters for oncology infusion billing, outpatient pharmacy administration tracking, and payer coverage policies that determine patient access to guideline-directed supportive care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for palonosetron use, typical sites of service where J2469 is billed, and common billing practices. The publication also summarizes payer coverage patterns, reimbursement benchmarks, and relevant policy considerations that affect how the code is applied in practice.
The report explains coding conventions for reporting the drug administration line, highlights typical documentation elements required for reimbursement, and outlines where variations in coverage or prior authorization commonly occur. Data not available in the input is clearly noted where applicable. This resource is intended for billing professionals, practice managers, and policy analysts seeking a rapid national-level briefing on HCPCS Level II code J2469.
Billing Code Overview
HCPCS Level II code J2469 represents an injection of palonosetron hydrochloride, dosed at 25 mcg. This code is used to report the administration of a single-dose injectable antiemetic medication commonly used to prevent chemotherapy-induced nausea and vomiting.
Service type: Injection / Therapeutic, antiemetic
Typical site of service: Outpatient infusion center, oncology clinic, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 56-year-old female scheduled to receive intravenous chemotherapy for breast cancer who requires prophylaxis against chemotherapy-induced nausea and vomiting. Prior to the infusion, the oncology nurse administers a single-dose IV injection of palonosetron 25 mcg (J2469) in the clinic infusion chair or outpatient oncology infusion center. The medication is documented in the infusion record with time, lot number, dose, route (intravenous), and the administering clinician. The workflow includes medication verification by pharmacy, order entry in the electronic health record, nurse administration with patient education about expected effects, and monitoring for adverse reactions for 30–60 minutes. Typical sites of service are outpatient hospital infusion centers, physician offices, and freestanding oncology infusion clinics. Common scenarios also include post-operative nausea prophylaxis for patients undergoing ambulatory surgery where a single IV dose of palonosetron is given intraoperatively or in the PACU prior to discharge.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Administrative claim adjustment | Rarely used; indicates an adjustment to a prior administrative claim when required by payer rules. |